Mode
Text Size
Log in / Sign up
Phase 2 N=35 Randomized Single-blind Treatment

Effects of CoSeal on Bleeding & Adhesions in Pediatric Heart Surgery

Congenital Heart Defect · Surgery-Induced Tissue Adhesions · Hemorrhage

Enrolled (actual)
35
Serious AEs
11.4%
Results posted
Aug 2016
Primary outcome: Primary: Severity of Adhesions at the Retrosternal Site — 0; 31.3; 0; 37.5 percentage of participants

Study Design & Population

Study type
Interventional
Phase
Phase 2
Interventions
CoSeal Surgical Spray Group (Device)
Age
Pediatric
Sex
All
Sponsor
Loma Linda University
Primary completion
Aug 2015

Outcome Measures

OutcomeResultp-value
PRIMARY
Severity of Adhesions at the Retrosternal Site
0; 31.3; 0; 37.5; 0; 18.8
PRIMARY
Severity of Adhesions at the Arterial Base Site.
0; 12.5; 0; 43.8; 7.1; 25.0
PRIMARY
Severity of Adhesions at the Diaphragm Site
0; 0; 0; 85.7; 0; 14.3
PRIMARY
Severity of Adhesions at the Left Lateral Site
0; 8.3; 0; 50.0; 0; 8.3
PRIMARY
Severity of Adhesions at the Right Lateral Site
0; 6.3; 0; 25.0; 7.7; 50.0
PRIMARY
Post-operative Bleeding
106.38; 108.64
PRIMARY
Adhesion Burden
37.39; 23.44
SECONDARY
Hospital Stay
4.75; 6.29

Summary

This is a prospective, randomized, open-label, blinded-evaluator study that will evaluate the effectiveness of a surgical sealant (CoSeal) composed of biocompatible polyethylene glycol on the formation of mediastinal and pericardial adhesions in children undergoing staged surgical reconstruction (potential procedures include: Blalock-Taussig Type Operation, Classical Glenn Procedure, Bidirectional Glenn Procedure, Norwood). Additionally, bleeding will be evaluated by drainage post-operatively through surgical site drainage output.

Eligibility Criteria

Inclusion Criteria

  • Have an acceptable surrogate capable of giving consent on the subject's behalf.
  • Pediatric patients ages 0 - 17
  • Have a cardiac disease which requires staged cardiac surgery and resternotomy
  • Non-emergent state or emergent state with sufficient time to educate and consent

Exclusion Criteria

  • An immune system disorder
  • Unplanned reoperation
  • Known hypersensitivity to components in CoSeal
  • Patients undergoing reoperation less than 3 months after the primary surgery
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT01330433). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search